QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Parallel Viral Cultures Enable Accurate Modeling of Growth Rates
3.2. Comparison of HIVREJO.c Mutant Growth Rates via QuickFit
3.3. The High Sensitivity of QuickFit Allows for the Evaluation of Different HIV Isolates
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Wargo, A.R.; Kurath, G. Viral Fitness: Definitions, Measurement, and Current Insights. Curr. Opin. Virol. 2012, 2, 538–545. [Google Scholar] [CrossRef] [PubMed]
- Domingo, E. Mechanisms of Viral Emergence. Vet. Res. 2010, 41, 38. [Google Scholar] [CrossRef] [PubMed]
- Sanjuán, R.; Domingo-Calap, P. Genetic Diversity and Evolution of Viral Populations. In Encyclopedia of Virology; Elsevier: Amsterdam, The Netherlands, 2021; pp. 53–61. ISBN 978-0-12-814516-6. [Google Scholar]
- Lombart, J.P.; Vray, M.; Kafando, A.; Lemée, V.; Ouédraogo-Traoré, R.; Corrigan, G.E.; Plantier, J.-C.; Simon, F.; Braun, J. Plasma Virion Reverse Transcriptase Activity and Heat Dissociation-Boosted P24 Assay for HIV Load in Burkina Faso, West Africa. AIDS 2005, 19, 1273–1277. [Google Scholar] [CrossRef] [PubMed]
- Campbell, T.B.; Schneider, K.; Wrin, T.; Petropoulos, C.J.; Connick, E. Relationship between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus Load in Plasma. J. Virol. 2003, 77, 12105–12112. [Google Scholar] [CrossRef] [PubMed]
- Klein, S.A.; Karsten, S.; Rüster, B.; Klebba, C.; Pape, M.; Ottmann, O.G.; Hoelzer, D.; Roth, W.K. Comparison of TaqManTM Real-Time PCR and P24 Elisa for Quantification of In Vitro HIV-1 Replication. J. Virol. Methods 2003, 107, 169–175. [Google Scholar] [CrossRef] [PubMed]
- Deeks, S.G.; Overbaugh, J.; Phillips, A.; Buchbinder, S. HIV Infection. Nat. Rev. Dis. Primer 2015, 1, 15035. [Google Scholar] [CrossRef] [PubMed]
- Eggleton, J.S.; Nagalli, S. Highly Active Antiretroviral Therapy (HAART). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Hillis, A.; Germain, J.; Hope, V.; McVeigh, J.; Van Hout, M.C. Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. AIDS Behav. 2020, 24, 3056–3070. [Google Scholar] [CrossRef] [PubMed]
- Murchu, E.O.; Marshall, L.; Teljeur, C.; Harrington, P.; Hayes, C.; Moran, P.; Ryan, M. Oral Pre-Exposure Prophylaxis (PrEP) to Prevent HIV: A Systematic Review and Meta-Analysis of Clinical Effectiveness, Safety, Adherence and Risk Compensation in All Populations. BMJ Open 2022, 12, e048478. [Google Scholar] [CrossRef] [PubMed]
- Günthard, H.F.; Saag, M.S.; Benson, C.A.; Del Rio, C.; Eron, J.J.; Gallant, J.E.; Hoy, J.F.; Mugavero, M.J.; Sax, P.E.; Thompson, M.A.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel. JAMA 2016, 316, 191. [Google Scholar] [CrossRef]
- Chávez-Hernández, A.L.; Juárez-Mercado, K.E.; Saldívar-González, F.I.; Medina-Franco, J.L. Towards the De Novo Design of HIV-1 Protease Inhibitors Based on Natural Products. Biomolecules 2021, 11, 1805. [Google Scholar] [CrossRef]
- Fofana, D.B.; Diarra, H.; Guindo, I.; Savadogo, M.K.; d’Almeida, M.; Diallo, F.I.; Baldé, A.; Soulié, C.; Kone, A.; Marcelin, A.-G.; et al. Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children. Viruses 2023, 15, 546. [Google Scholar] [CrossRef] [PubMed]
- Dybul, M.; Attoye, T.; Baptiste, S.; Cherutich, P.; Dabis, F.; Deeks, S.G.; Dieffenbach, C.; Doehle, B.; Goodenow, M.M.; Jiang, A.; et al. The Case for an HIV Cure and How to Get There. Lancet HIV 2021, 8, e51–e58. [Google Scholar] [CrossRef]
- Mohri, H.; Markowitz, M. In Vitro Characterization of Multidrug-Resistant HIV-1 Isolates from a Recently Infected Patient Associated with Dual Tropism and Rapid Disease Progression. J. Acquir. Immune Defic. Syndr. 1999 2008, 48, 511–521. [Google Scholar] [CrossRef]
- Kandeel, M. The Impact of the M184V Resistance Mutation on Treatment Outcomes in Patients with HIV Infection: A Systematic Review and Meta-Analysis. AIDS Rev. 2023, 26, 136–144. [Google Scholar] [CrossRef] [PubMed]
- Shao, W.; Boltz, V.F.; Hattori, J.; Bale, M.J.; Maldarelli, F.; Coffin, J.M.; Kearney, M.F. Short Communication: HIV-DRLink: A Tool for Reporting Linked HIV-1 Drug Resistance Mutations in Large Single-Genome Data Sets Using the Stanford HIV Database. AIDS Res. Hum. Retroviruses 2020, 36, 942–947. [Google Scholar] [CrossRef]
- Zanini, F.; Puller, V.; Brodin, J.; Albert, J.; Neher, R.A. In Vivo Mutation Rates and the Landscape of Fitness Costs of HIV-1. Virus Evol. 2017, 3, vex003. [Google Scholar] [CrossRef] [PubMed]
- Kühnert, D.; Kouyos, R.; Shirreff, G.; Pečerska, J.; Scherrer, A.U.; Böni, J.; Yerly, S.; Klimkait, T.; Aubert, V.; Günthard, H.F.; et al. Quantifying the Fitness Cost of HIV-1 Drug Resistance Mutations through Phylodynamics. PLoS Pathog. 2018, 14, e1006895. [Google Scholar] [CrossRef]
- Cong, M.; Heneine, W.; García-Lerma, J.G. The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions. J. Virol. 2007, 81, 3037–3041. [Google Scholar] [CrossRef]
- Chen, J.; Zhou, T.; Zhang, Y.; Luo, S.; Chen, H.; Chen, D.; Li, C.; Li, W. The Reservoir of Latent HIV. Front. Cell. Infect. Microbiol. 2022, 12, 945956. [Google Scholar] [CrossRef]
- Wang, Z.; Simonetti, F.R.; Siliciano, R.F.; Laird, G.M. Measuring Replication Competent HIV-1: Advances and Challenges in Defining the Latent Reservoir. Retrovirology 2018, 15, 21. [Google Scholar] [CrossRef]
- Vetter, B.N.; Orlowski, V.; Niederhauser, C.; Walter, L.; Schüpbach, J. Impact of Naturally Occurring Amino Acid Variations on the Detection of HIV-1 P24 in Diagnostic Antigen Tests. BMC Infect. Dis. 2015, 15, 468. [Google Scholar] [CrossRef] [PubMed]
- Vetter, B.N.; Orlowski, V.; Fransen, K.; Niederhauser, C.; Aubert, V.; Brandenberger, M.; Ciardo, D.; Dollenmaier, G.; Klimkait, T.; Regenass, S.; et al. Generation of a Recombinant Gag Virus-like-Particle Panel for the Evaluation of P24 Antigen Detection by Diagnostic HIV Tests. PLoS ONE 2014, 9, e111552. [Google Scholar] [CrossRef] [PubMed]
- Molina, M.A.; Vink, M.; Berkhout, B.; Herrera-Carrillo, E. In-House ELISA Protocols for Capsid P24 Detection of Diverse HIV Isolates. Virol. J. 2023, 20, 269. [Google Scholar] [CrossRef] [PubMed]
- Fan, P.; Li, X.; Su, W.; Kong, W.; Kong, X.; Wang, Z.; Wang, Y.; Jiang, C.; Gao, F. Enhanced Sensitivity for Detection of HIV-1 P24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay. PLoS ONE 2015, 10, e0125701. [Google Scholar] [CrossRef] [PubMed]
- Levinger, C.; Howard, J.N.; Cheng, J.; Tang, P.; Joshi, A.; Catalfamo, M.; Bosque, A. An Ultrasensitive Planar Array P24 Gag ELISA to Detect HIV-1 in Diverse Biological Matrixes. Sci. Rep. 2021, 11, 23682. [Google Scholar] [CrossRef]
- Naranbhai, V.; Nathan, A.; Kaseke, C.; Berrios, C.; Khatri, A.; Choi, S.; Getz, M.A.; Tano-Menka, R.; Ofoman, O.; Gayton, A.; et al. T Cell Reactivity to the SARS-CoV-2 Omicron Variant Is Preserved in Most but Not All Individuals. Cell 2022, 185, 1041–1051.e6. [Google Scholar] [CrossRef] [PubMed]
- Balazs, A.B.; Ouyang, Y.; Hong, C.M.; Chen, J.; Nguyen, S.M.; Rao, D.S.; An, D.S.; Baltimore, D. Vectored Immunoprophylaxis Protects Humanized Mice from Mucosal HIV Transmission. Nat. Med. 2014, 20, 296–300. [Google Scholar] [CrossRef]
- Platt, E.J.; Wehrly, K.; Kuhmann, S.E.; Chesebro, B.; Kabat, D. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 1998, 72, 2855–2864. [Google Scholar] [CrossRef] [PubMed]
- Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O’Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of Gp120. J. Virol. 2000, 74, 8358–8367. [Google Scholar] [CrossRef]
- Platt, E.J.; Bilska, M.; Kozak, S.L.; Kabat, D.; Montefiori, D.C. Evidence That Ecotropic Murine Leukemia Virus Contamination in TZM-Bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1. J. Virol. 2009, 83, 8289–8292. [Google Scholar] [CrossRef]
- Takeuchi, Y.; McClure, M.O.; Pizzato, M. Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research. J. Virol. 2008, 82, 12585–12588. [Google Scholar] [CrossRef]
- Wang, S.; Zhou, Q.; Chen, X.; Luo, R.-H.; Li, Y.; Liu, X.; Yang, L.-M.; Zheng, Y.-T.; Wang, P. Modification of N-Terminal α-Amine of Proteins via Biomimetic Ortho-Quinone-Mediated Oxidation. Nat. Commun. 2021, 12, 2257. [Google Scholar] [CrossRef]
- Fassy, J.; Lacoux, C.; Leroy, S.; Noussair, L.; Hubac, S.; Degoutte, A.; Vassaux, G.; Leclercq, V.; Rouquié, D.; Marquette, C.-H.; et al. Versatile and Flexible Microfluidic qPCR Test for High-Throughput SARS-CoV-2 and Cellular Response Detection in Nasopharyngeal Swab Samples. PloS ONE 2021, 16, e0243333. [Google Scholar] [CrossRef] [PubMed]
- Sentmanat, M.; Kouranova, E.; Cui, X. One-Step RNA Extraction for RT-qPCR Detection of 2019-nCoV 2020. bioRxiv 2020. bioRxiv:2020.04.02.022384. [Google Scholar]
- Ladha, A.; Joung, J.; Abudayyeh, O.O.; Gootenberg, J.S.; Zhang, F. A 5-Min RNA Preparation Method for COVID-19 Detection with RT-qPCR 2020. medRxiv 2020. medRxiv:2020.05.07.20055947. [Google Scholar]
- Traynard, P.; Ayral, G.; Twarogowska, M.; Chauvin, J. Efficient Pharmacokinetic Modeling Workflow with the MonolixSuite: A Case Study of Remifentanil. CPT Pharmacomet. Syst. Pharmacol. 2020, 9, 198–210. [Google Scholar] [CrossRef]
- Chan, P.L.S.; Jacqmin, P.; Lavielle, M.; McFadyen, L.; Weatherley, B. The Use of the SAEM Algorithm in MONOLIX Software for Estimation of Population Pharmacokinetic-Pharmacodynamic-Viral Dynamics Parameters of Maraviroc in Asymptomatic HIV Subjects. J. Pharmacokinet. Pharmacodyn. 2011, 38, 41–61. [Google Scholar] [CrossRef]
- Ochsenbauer, C.; Edmonds, T.G.; Ding, H.; Keele, B.F.; Decker, J.; Salazar, M.G.; Salazar-Gonzalez, J.F.; Shattock, R.; Haynes, B.F.; Shaw, G.M.; et al. Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. J. Virol. 2012, 86, 2715–2728. [Google Scholar] [CrossRef] [PubMed]
- Brady, J.M.; Phelps, M.; MacDonald, S.W.; Lam, E.C.; Nitido, A.; Parsons, D.; Boutros, C.L.; Deal, C.E.; Garcia-Beltran, W.F.; Tanno, S.; et al. Antibody-Mediated Prevention of Vaginal HIV Transmission Is Dictated by IgG Subclass in Humanized Mice. Sci. Transl. Med. 2022, 14, eabn9662. [Google Scholar] [CrossRef]
- Diallo, K.; Götte, M.; Wainberg, M.A. Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 2003, 47, 3377–3383. [Google Scholar] [CrossRef]
- Gu, Z.; Gao, Q.; Li, X.; Parniak, M.A.; Wainberg, M.A. Novel Mutation in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Encodes Cross-Resistance to 2’,3’-Dideoxyinosine and 2’,3’-Dideoxycytidine. J. Virol. 1992, 66, 7128–7135. [Google Scholar] [CrossRef]
- Back, N.K.; Nijhuis, M.; Keulen, W.; Boucher, C.A.; Oude Essink, B.O.; van Kuilenburg, A.B.; van Gennip, A.H.; Berkhout, B. Reduced Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme. EMBO J. 1996, 15, 4040–4049. [Google Scholar] [CrossRef] [PubMed]
- Margot, N.; Ram, R.; Abram, M.; Haubrich, R.; Callebaut, C. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V. Antimicrob. Agents Chemother. 2020, 64, e02557-19. [Google Scholar] [CrossRef] [PubMed]
- Rossignol, E.D.; Dugast, A.-S.; Compere, H.; Cottrell, C.A.; Copps, J.; Lin, S.; Cizmeci, D.; Seaman, M.S.; Ackerman, M.E.; Ward, A.B.; et al. Mining HIV Controllers for Broad and Functional Antibodies to Recognize and Eliminate HIV-Infected Cells. Cell Rep. 2021, 35, 109167. [Google Scholar] [CrossRef]
- Dingens, A.S.; Acharya, P.; Haddox, H.K.; Rawi, R.; Xu, K.; Chuang, G.-Y.; Wei, H.; Zhang, B.; Mascola, J.R.; Carragher, B.; et al. Complete Functional Mapping of Infection- and Vaccine-Elicited Antibodies against the Fusion Peptide of HIV. PLoS Pathog. 2018, 14, e1007159. [Google Scholar] [CrossRef] [PubMed]
- Ribeiro, R.M.; Qin, L.; Chavez, L.L.; Li, D.; Self, S.G.; Perelson, A.S. Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. J. Virol. 2010, 84, 6096–6102. [Google Scholar] [CrossRef] [PubMed]
- Dykes, C.; Demeter, L.M. Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 2007, 20, 550–578. [Google Scholar] [CrossRef]
- Quiñones-Mateu, M.E.; Arts, E.J. Fitness of Drug Resistant HIV-1: Methodology and Clinical Implications. Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 2002, 5, 224–233. [Google Scholar] [CrossRef]
- Ali, A.; Yang, O.O. A Novel Small Reporter Gene and HIV-1 Fitness Assay. J. Virol. Methods 2006, 133, 41–47. [Google Scholar] [CrossRef]
- Nankya, I.L.; Tebit, D.M.; Abraha, A.; Kyeyune, F.; Gibson, R.; Jegede, O.; Nickel, G.; Arts, E.J. Defining the Fitness of HIV-1 Isolates with Dual/Mixed Co-Receptor Usage. AIDS Res. Ther. 2015, 12, 34. [Google Scholar] [CrossRef]
- Quiñones-Mateu, M.E.; Ball, S.C.; Marozsan, A.J.; Torre, V.S.; Albright, J.L.; Vanham, G.; van Der Groen, G.; Colebunders, R.L.; Arts, E.J. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression. J. Virol. 2000, 74, 9222–9233. [Google Scholar] [CrossRef]
- Weber, J.; Gibson, R.M.; Sácká, L.; Strunin, D.; Hodek, J.; Weberová, J.; Pávová, M.; Alouani, D.J.; Asaad, R.; Rodriguez, B.; et al. Impaired Human Immunodeficiency Virus Type 1 Replicative Fitness in Atypical Viremic Non-Progressor Individuals. AIDS Res. Ther. 2017, 14, 15. [Google Scholar] [CrossRef]
- Tebit, D.M.; Nickel, G.; Gibson, R.; Rodriguez, M.; Hathaway, N.J.; Bain, K.; Reyes-Rodriguez, A.L.; Ondoa, P.; Heeney, J.L.; Li, Y.; et al. Replicative Fitness and Pathogenicity of Primate Lentiviruses in Lymphoid Tissue, Primary Human and Chimpanzee Cells: Relation to Possible Jumps to Humans. EBioMedicine 2024, 100, 104965. [Google Scholar] [CrossRef]
- Rindler, A.E.; Kuster, H.; Neumann, K.; Leemann, C.; Braun, D.L.; Metzner, K.J.; Günthard, H.F. A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. Viruses 2021, 13, 404. [Google Scholar] [CrossRef]
- Metzner, K.J.; Giulieri, S.G.; Knoepfel, S.A.; Rauch, P.; Burgisser, P.; Yerly, S.; Günthard, H.F.; Cavassini, M. Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and -Adherent Patients. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2009, 48, 239–247. [Google Scholar] [CrossRef] [PubMed]
- Weber, J.; Rangel, H.R.; Chakraborty, B.; Tadele, M.; Martinez, M.A.; Martinez-Picado, J.; Marotta, M.L.; Mirza, M.; Ruiz, L.; Clotet, B.; et al. A Novel TaqMan Real-Time PCR Assay to Estimate Ex Vivo Human Immunodeficiency Virus Type 1 Fitness in the Era of Multi-Target (Pol and Env) Antiretroviral Therapy. J. Gen. Virol. 2003, 84, 2217–2228. [Google Scholar] [CrossRef] [PubMed]
- Lilyanna, S.; Ng, E.M.W.; Moriguchi, S.; Chan, S.P.; Kokawa, R.; Huynh, S.H.; Chong, P.C.J.; Ng, Y.X.; Richards, A.M.; Ng, T.W.; et al. Variability in Microplate Surface Properties and Its Impact on ELISA. J. Appl. Lab. Med. 2018, 2, 687–699. [Google Scholar] [CrossRef] [PubMed]
- Larsen, S.E.; Berube, B.J.; Pecor, T.; Cross, E.; Brown, B.P.; Williams, B.D.; Johnson, E.; Qu, P.; Carter, L.; Wrenn, S.; et al. Qualification of ELISA and Neutralization Methodologies to Measure SARS-CoV-2 Humoral Immunity Using Human Clinical Samples. J. Immunol. Methods 2021, 499, 113160. [Google Scholar] [CrossRef]
- Natarajan, S.; Remick, D.G. The ELISA Standard Save: Calculation of Sample Concentrations in Assays with a Failed Standard Curve. J. Immunol. Methods 2008, 336, 242–245. [Google Scholar] [CrossRef]
- Kibirige, C.N.; Manak, M.; King, D.; Abel, B.; Hack, H.; Wooding, D.; Liu, Y.; Fernandez, N.; Dalel, J.; Kaye, S.; et al. Development of a Sensitive, Quantitative Assay with Broad Subtype Specificity for Detection of Total HIV-1 Nucleic Acids in Plasma and PBMC. Sci. Rep. 2022, 12, 1550. [Google Scholar] [CrossRef]
- Nyirenda, J.T.; Henrion, M.Y.R.; Nyasulu, V.; Msakwiza, M.; Nedi, W.; Thole, H.; Phulusa, J.; Toto, N.; Jere, K.C.; Winter, A.; et al. Examination of ELISA against PCR for Assessing Treatment Efficacy against Cryptosporidium in a Clinical Trial Context. PloS ONE 2023, 18, e0289929. [Google Scholar] [CrossRef] [PubMed]
- Hijjawi, N.; Yang, R.; Hatmal, M.; Yassin, Y.; Mharib, T.; Mukbel, R.; Mahmoud, S.A.; Al-Shudifat, A.-E.; Ryan, U. Comparison of ELISA, Nested PCR and Sequencing and a Novel qPCR for Detection of Giardia Isolates from Jordan. Exp. Parasitol. 2018, 185, 23–28. [Google Scholar] [CrossRef] [PubMed]
- Gueudin, M.; Leoz, M.; Lemée, V.; De Oliveira, F.; Vessière, A.; Kfutwah, A.; Plantier, J.-C. A New Real-Time Quantitative PCR for Diagnosis and Monitoring of HIV-1 Group O Infection. J. Clin. Microbiol. 2012, 50, 831–836. [Google Scholar] [CrossRef] [PubMed]
- Marino-Merlo, F.; Stefanizzi, V.; Ragno, A.; Piredda, L.; Grelli, S.; Macchi, B.; Mastino, A. Quantitative Evaluation of Very Low Levels of HIV-1 Reverse Transcriptase by a Novel Highly Sensitive RT-qPCR Assay. Life 2022, 12, 1130. [Google Scholar] [CrossRef]
- Perelson, A.S.; Nelson, P.W. Mathematical Analysis of HIV-1 Dynamics In Vivo. SIAM Rev. 1999, 41, 3–44. [Google Scholar] [CrossRef]
- Iwami, S.; Sato, K.; De Boer, R.J.; Aihara, K.; Miura, T.; Koyanagi, Y. Identifying Viral Parameters from In Vitro Cell Cultures. Front. Microbiol. 2012, 3, 319. [Google Scholar] [CrossRef] [PubMed]
- Khan, S.U.; Ullah, S.; Li, S.; Mostafa, A.M.; Bilal Riaz, M.; AlQahtani, N.F.; Teklu, S.W. A Novel Simulation-Based Analysis of a Stochastic HIV Model with the Time Delay Using High Order Spectral Collocation Technique. Sci. Rep. 2024, 14, 7961. [Google Scholar] [CrossRef] [PubMed]
- D’Orso, I.; Forst, C.V. Mathematical Models of HIV-1 Dynamics, Transcription, and Latency. Viruses 2023, 15, 2119. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Kuga, K.; Ito, K. Visual Prediction and Parameter Optimization of Viral Dynamics in the Mucus Milieu of the Upper Airway Based on CFPD-HCD Analysis. Comput. Methods Programs Biomed. 2023, 238, 107622. [Google Scholar] [CrossRef]
- Thingstad, T.F.; Pree, B.; Giske, J.; Våge, S. What Difference Does It Make If Viruses Are Strain-, Rather than Species-Specific? Front. Microbiol. 2015, 6, 320. [Google Scholar] [CrossRef]
- Thingstad, T.F.; Våge, S.; Storesund, J.E.; Sandaa, R.-A.; Giske, J. A Theoretical Analysis of How Strain-Specific Viruses Can Control Microbial Species Diversity. Proc. Natl. Acad. Sci. USA 2014, 111, 7813–7818. [Google Scholar] [CrossRef] [PubMed]
- Jones, B.R.; Joy, J.B. Simulating within Host Human Immunodeficiency Virus 1 Genome Evolution in the Persistent Reservoir. Virus Evol. 2020, 6, veaa089. [Google Scholar] [CrossRef] [PubMed]
- Frost, S.D.; Nijhuis, M.; Schuurman, R.; Boucher, C.A.; Brown, A.J. Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: The Relative Roles of Drift and Selection. J. Virol. 2000, 74, 6262–6268. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.; Kuritzkes, D.R. Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1. J. Virol. 2011, 85, 11309–11314. [Google Scholar] [CrossRef] [PubMed]
- Delaunay, C.; Brun-Vézinet, F.; Landman, R.; Collin, G.; Peytavin, G.; Trylesinski, A.; Flandre, P.; Miller, M.; Descamps, D. Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021). J. Virol. 2005, 79, 9572–9578. [Google Scholar] [CrossRef] [PubMed]
- Schuurman, R.; Nijhuis, M.; van Leeuwen, R.; Schipper, P.; de Jong, D.; Collis, P.; Danner, S.A.; Mulder, J.; Loveday, C.; Christopherson, C. Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC). J. Infect. Dis. 1995, 171, 1411–1419. [Google Scholar] [CrossRef] [PubMed]
- Vicenzi, E.; Liò, P.; Poli, G. The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection. Theranostics 2013, 3, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Fenton, A.D.; Archin, N.; Turner, A.-M.; Joseph, S.; Moeser, M.; Margolis, D.M.; Browne, E.P. A Novel High-Throughput Microwell Outgrowth Assay for HIV-Infected Cells. J. Virol. 2024, 98, e0179823. [Google Scholar] [CrossRef] [PubMed]
- Salasc, F.; Gludish, D.W.; Jarvis, I.; Boliar, S.; Wills, M.R.; Russell, D.G.; Lever, A.M.L.; Mok, H.-P. A Novel, Sensitive Dual-Indicator Cell Line for Detection and Quantification of Inducible, Replication-Competent Latent HIV-1 from Reservoir Cells. Sci. Rep. 2019, 9, 19325. [Google Scholar] [CrossRef] [PubMed]
- Jamburuthugoda, V.K.; Santos-Velazquez, J.M.; Skasko, M.; Operario, D.J.; Purohit, V.; Chugh, P.; Szymanski, E.A.; Wedekind, J.E.; Bambara, R.A.; Kim, B. Reduced dNTP Binding Affinity of 3TC-Resistant M184I HIV-1 Reverse Transcriptase Variants Responsible for Viral Infection Failure in Macrophage. J. Biol. Chem. 2008, 283, 9206–9216. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galvez, N.M.S.; Sheehan, M.L.; Lin, A.Z.; Cao, Y.; Lam, E.C.; Jackson, A.M.; Balazs, A.B. QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro. Viruses 2024, 16, 1320. https://doi.org/10.3390/v16081320
Galvez NMS, Sheehan ML, Lin AZ, Cao Y, Lam EC, Jackson AM, Balazs AB. QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro. Viruses. 2024; 16(8):1320. https://doi.org/10.3390/v16081320
Chicago/Turabian StyleGalvez, Nicolas M. S., Maegan L. Sheehan, Allen Z. Lin, Yi Cao, Evan C. Lam, Abigail M. Jackson, and Alejandro B. Balazs. 2024. "QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro" Viruses 16, no. 8: 1320. https://doi.org/10.3390/v16081320